HEMOSTASIS COAGULATION ROUTINE REAGENTS INHIBITOR NIJMEGEN BETHESDA ASSAYS FIX INHIBITOR NIJMEGEN BETHESDA CONTROLS
Factor IX Inhibitor Plasma Weak Control
Factor IX deficient plasma without Factor IX inhibitor.
This plasma can be used for the control of the determination of Factor IX (FIX) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.
Factor IX Inhibitor Plasma Weak Control is produced from factor IX deficient human plasma to which an inhibitor antibody was added in order to provide a precise neutralizing activity.
Informations
Treatment for hemophilia B involves injecting the missing Factor IX I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FIX, called inhibitors.
The development of an anti-FIX inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assays or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FIX for hemophilia B.
Documentation
Download the product sheetPrice list, safety data sheets and notices are accessible to our registered customers.
Nijmegen Bethesda Controls
References
| 6-1900-ID | Vial | 25 x 0.5 mL |
